FindTrial
Sign In

Tisleizumab(BGB-A317)

DRUG3 trials

Sponsors

Sun Yat-sen University, Tao Zhang, Samsung Medical Center

Conditions

Anti PD-1DMMR Colorectal CancerImmunotherapyLocally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaLocally Advanced Rectal Cancer (LARC)Metastatic Colorectal Cancer (mCRC)Neoadjuvant TherapyRefractory Solid Cancer Patients Unexposed to Immunotherapy

Phase 2

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
RecruitingNCT06262581
Sun Yat-sen UniversityAnti PD-1, DMMR Colorectal Cancer, Immunotherapy
Start: 2023-09-23End: 2025-12-31Target: 40Updated: 2024-02-16
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Not yet recruitingNCT07243938
Tao ZhangLocally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Colorectal Cancer (mCRC) +1
Start: 2026-01-15End: 2031-06-01Target: 70Updated: 2025-11-24
T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
Not yet recruitingNCT07300891
Samsung Medical CenterRefractory Solid Cancer Patients Unexposed to Immunotherapy
Start: 2026-01-31End: 2028-01-31Target: 72Updated: 2025-12-24